Myriel

Executive Summary

Myriel is a privately held biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in developing novel small molecule therapies for protein misfolding diseases, with a primary focus on neurodegenerative conditions such as dementia. Myriel leverages computational drug discovery to identify compounds that target the root cause of synaptic weakening in dementia. Its lead program aims to rapidly reverse memory loss by inhibiting a specific tau cleavage event, an approach that could address a critical unmet need in Alzheimer's disease and related disorders. The company's platform integrates advanced computational models with experimental validation to accelerate the discovery of disease-modifying therapies.

Upcoming Catalysts (preview)

• Q4 2026Lead program preclinical data release or IND filing40% success
• Q3 2026Series A funding round completion60% success
• TBDPotential partnership or licensing deal for tau-targeting platform30% success